Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Raises Caution for Use of Harvoni, 7 Other Hep C Drugs in HBV Carriers
May 19, 2016
- Clinical Research Bill to Enter Diet Deliberations on May 20, Might Be Enacted June 1
May 19, 2016
- MOF Panel Recommends Full Rollout of Cost-Effective Evaluations
May 19, 2016
- LDP Bigwig Questions Costly Meds Reimbursement without Politicians’ Input
May 19, 2016
- Draft of Govt’s Economic, Fiscal Policy Blueprint Mentions “Optimal Use of Innovative Drugs”
May 19, 2016
- Standard Operating Profit Rate for Cost Calculation Pricing Rule Updated to 14.6%: Chuikyo
May 19, 2016
- Pricy Meds Again a Hot Topic at Chuikyo, MHLW Set to Launch Concrete Discussions
May 19, 2016
- AMED Initiates Project to Create Integrated Database for Clinical Genome Information
May 19, 2016
- Industry Opposes to Market Price Survey for Possible 2017 Revision; “No Reason to Conduct Survey if Sales Tax Hike Is Postponed”: FPMAJ Chairman
May 19, 2016
- Chuikyo OKs 16 APIs for Listing on May 25, Novartis’s Melanoma Combo Gets 45% Price Premium
May 18, 2016
- MHLW Advisory Panel to Discuss ASKA’s Hepatic Encephalopathy Treatment on May 30
May 18, 2016
- MHLW Advisory Panel to Discuss Sanofi’s PCSK9 Inhibitor on May 27
May 16, 2016
- Clinical Research Bill OK’ed by Cabinet, Now Up for Diet Deliberations
May 13, 2016
- MHLW Study Group Agrees MID-NET Database Should Be Made Available for Use in Post-Marketing Surveillance
May 13, 2016
- MHLW Panel Snubs 10-Valent Synflorix for Public Immunization Program
May 12, 2016
- Abe Tells Key Govt Panel to Compile FY2016 Economic, Fiscal Blueprint by May-End
May 12, 2016
- National Cancer Center to Strengthen Systems for Genome-Based Personalized Medicine and Rare Cancers: Pres. Nakagama
May 12, 2016
- MHLW Orders Teijin Pharma to Review Documents Submitted for Reexamination of 6 Products Including Bonalon
May 12, 2016
- Pharmacists Can Make Big Contribution to Health Finances by Reducing Drug Waste: MHLW Study Group Chief
May 10, 2016
- 18 of 24 Drug Firms in Kumamoto Have No Production Problem after Quakes: MHLW Update
May 10, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…